Article 2: The World’s Pharmacy Has a Challenge — Shifting from Volume to Value
Why in News: India’s pharmaceutical sector is being urged to move from high-volume generic manufacturing to high-value innovation-led growth to sustain global leadership.
Key Details
- India produces about 60% of global vaccine demand and is a major supplier of generic medicines worldwide.
- Despite scale, India accounts for only ~6% of global pharma market value, indicating a value gap.
- Policy frameworks like the Indian Patents Act, 1970 and the Hatch-Waxman Act, 1984 enabled the global generic revolution.
- Achieving the $350-billion pharma export target by 2047 requires innovation, biologics, and R&D investment.
India as the “Pharmacy of the World”
- Global Generic Leadership: India supplies a large share of affordable medicines globally and is among the top providers of generic drugs to the United States and developing countries. This has significantly improved drug accessibility.
- Impact on Global Health: Affordable antiretroviral drugs and TB medicines from Indian firms helped reduce global AIDS and TB mortality by nearly 85% over the past decades, highlighting India’s humanitarian role.
- USFDA-Approved Manufacturing Base: India hosts more than one-third of USFDA-approved manufacturing plants outside the US, demonstrating compliance with stringent global quality standards.
- Export Footprint: Indian pharmaceuticals are exported to 200+ countries, making the sector a major contributor to India’s soft power and trade earnings.
Policy Foundations of India’s Pharma Success
- Indian Patents Act, 1970: The shift from product patents to process patents enabled Indian firms to reverse-engineer drugs and produce low-cost generics, fostering domestic industry growth.
- Global Policy Complementarity: The US Hatch-Waxman Act (1984) created an abbreviated approval pathway for generics, expanding global demand for affordable medicines.
- Affordability–Availability Framework: Both India and the US pursued policies aimed at improving drug affordability and competition, showing how policy entrepreneurship can shape industrial success.
- Entrepreneurial Ecosystem: Visionary industry leaders built globally competitive firms, demonstrating the importance of state–private sector partnership in strategic industries.
Structural Strengths of India’s Pharma Sector
- Cost Competitiveness: India benefits from low-cost skilled manpower and strong chemistry capabilities, enabling competitive generic manufacturing.
- Large Domestic Market: India’s domestic pharmaceutical consumption now roughly equals its exports, providing a stable demand base for firms.
- Strong Generics Ecosystem: Generics account for a very high share of prescriptions in developed markets (e.g., about 90% in the US), where Indian firms have strong presence.
- Soft Power and Health Diplomacy: India’s supply of affordable medicines during global health crises has strengthened its global health leadership and diplomatic goodwill.
The Core Challenge — From Volume to Value
- Value Share Gap: While India produces a large share of medicines by volume, it captures only around 6% of global pharma value, reflecting low margins in generics.
- Limited Innovation Pipeline: India’s share in new drug discovery and patented medicines remains modest compared to the US, EU, and China.
- Dependence on Generics: Heavy reliance on off-patent drugs exposes the industry to price erosion and intense global competition.
- Global Competitive Pressure: Countries like China are investing heavily in biologics and fast-follower drugs, increasing competitive risks for India.
Emerging Opportunities for India Pharma 2.0
- Biologics and Biosimilars: The global shift toward biologic drugs offers India a major opportunity if it scales biotech manufacturing and regulatory capabilities.
- Innovation and R&D: Increasing investment in drug discovery, clinical trials, and research infrastructure can help India move up the pharmaceutical value chain.
- Contract Research and Manufacturing (CRAMS): Global firms are diversifying supply chains, creating opportunities for India in contract manufacturing and research services.
- Domestic Market Reforms: Improving distribution efficiency, digital health integration, and insurance penetration can expand high-value domestic demand.
- Export Diversification: Expanding into specialty drugs, complex generics, and regulated markets can boost export earnings.
Key Challenges Ahead
- Weak Science and Research Ecosystem: India’s R&D expenditure (~0.7% of GDP) remains low compared to major innovation economies, limiting breakthrough drug development.
- Risk Capital Constraints: Pharmaceutical innovation requires long-gestation funding, but India’s venture and risk financing ecosystem is still evolving.
- Ease of Doing Business Issues: Regulatory delays, compliance burdens, and pricing controls can discourage innovation investment.
- China Factor: China’s strong integration of education, manufacturing, and state support has enabled rapid progress in new drug development.
- Trade and IP Pressures: Free trade negotiations and intellectual property demands from developed countries may constrain India’s generic advantage.
Geopolitical and Economic Significance
- Strategic Sector: Pharmaceuticals are critical for health security, supply chain resilience, and strategic autonomy.
- Economic Power Linkage: Technological and manufacturing strength in pharma contributes to broader economic and geopolitical influence.
- China Comparison: China’s success in moving labour from agriculture to manufacturing highlights the importance of industrial upgrading, an area where India still lags.
- Trust-Based Reforms: Recent policy moves toward decriminalisation, deregulation, and digitisation aim to strengthen India’s innovation ecosystem.
Conclusion
India’s pharmaceutical success story demonstrates the power of policy–entrepreneurship partnership. However, sustaining leadership requires a decisive shift from low-margin generics to high-value innovation, biologics, and research-driven growth. Strengthening the science ecosystem, easing regulatory burdens, expanding risk capital, and deepening global integration will be essential for achieving the vision of making India a global pharma innovation hub by 2047.
EXPECTED QUESTION FOR UPSC CSE
Prelims MCQ
Q. India’s pharmaceutical industry is globally known primarily for:
(a) Patented drug discovery
(b) Generic drug manufacturing
(c) Vaccine imports
(d) Medical devices
Answer: (b)